Estrogen (E) and T 3 regulate gene expression by receptor mechanisms that may enable hormonal interplay affecting growth and metabolism. Prior studies of E and tamoxifen (TM) interplay with T 3 in female rats identified a subset of E responses that required T 3 for expression and exhibited large agonist responses to TM. In contrast, TM acted more like an antagonist in most T 3 -independent E responses. This study used male rats to further explore the role of T 3 in E effects on growth and metabolism, and the relation of such effects to changes in serum GH and IGF-I. Orchidectomized, hypothyroid rats were treated 6 wk with vehicle, E2 benzoate (E2B), or TM with or without T 3 . The following parameters were measured: body weight change; tibia length and bone mineral density; heart and kidney weight; food intake and body temperature; serum levels of glucose, cholesterol, triglycerides, GH, and IGF-I; seminal vesicle weight; and anterior pituitary levels of GH, PRL, glandular kallikrein, and total protein. Interplay with T 3 contributed to multiple E effects on growth and metabolism, and some E responses involved both T 3 -dependent and T 3 -independent components. Both E2B and TM increased serum GH, but the increases were poorly coupled to IGF-I. Correlation/regression analysis of individual rat data sets suggested distinct roles for GH and IGF-I in specific E effects. E2B and TM effects on somatic growth exhibited positive correlations with IGF-I and negative correlations with GH; effects on bone mineral density and triglycerides exhibited positive correlations with GH and negative correlations with IGF-I. Three pharmacologically distinct classes of in vivo E responses were identified in this study, and TM displayed a profile of biological activity that may be useful for men undergoing androgen-deprivation therapy. (Endocrinology 142:  4223-4235, 2001) 
E STROGENS (E) REGULATE THE growth and function
of female sex organs, but effects on bone have led to use for osteoporosis (1) . Conversely, selective estrogen receptor modulators (SERMs) such as tamoxifen (TM) and raloxifene inhibit E effects on the breast but mimic E effects on bone (2, 3) . This paradoxical pharmacology reflects the diversity of ER mechanisms, with SERMs interfering with mechanisms at some targets while activating those at others. The mechanisms involved in ER signaling are influenced by cell phenotype, the target gene, and the activity of other signaling networks (4 -6) . With regard to the latter, there is evidence that multiple ER mechanisms may enable interplay with other hormone signaling systems, including those for T 3 (7) (8) (9) (10) (11) (12) (13) .
T 3 regulates growth as well as energy and lipid and bone metabolism; E interplay with T 3 may provide a versatile mechanism for metabolic adaptations related to reproductive biology. The physiological relevance of such interplay has been explored in ovariectomized, hypothyroid female rats (14 -17) . The results identified a subset of E responses that are T 3 dependent; this includes effects on growth, bone mass, and triglycerides. T 3 -independent E responses include uterine growth and induction of pituitary PRL and kallikrein. Moreover, TM exhibited high agonist efficacy in T 3 -dependent responses but acted more like an antagonist in most T 3 -independent responses. These findings suggest that estrogens may mediate two distinct types of biological regulation. In T 3 -independent responses, E can be viewed as a primary driver that fully activates the ER mechanisms mediating the response, and SERMs appear to poorly activate such mechanisms. In T 3 -dependent responses, however, E can be viewed as a modulator whose responses rely on interplay with T 3 signaling mechanisms; such modulator actions are also activated by SERMs.
The concept of distinct primary driver and modulator actions may clarify E actions in complex physiological systems regulated by multiple hormones. Moreover, targeted activation of modulator responses by SERMs may benefit novel groups of patients. For example, androgen deprivation therapy used in men with disseminated prostate cancer can increase the risk of osteoporosis and bone fractures (18 -21) . Estrogens can induce a state of androgen deprivation that can avoid such risks (22) , but doses needed for satisfactory tumor responses are often toxic (23) , and even low doses evoke breast growth. On the other hand, use of SERMs during androgen deprivation therapy may well prevent osteoporosis with little risk of toxicity or breast growth. However, there is little information about SERM effects in men.
Animal studies of SERMs or their interplay with T 3 have also focused on females. Thus, it is unclear if males exhibit equivalent responses, and there are reasons why such equivalence should not be presumed. In particular, the GH-IGF-I axis is targeted by both T 3 and estrogens, and some estrogen effects on growth and metabolism have been proposed to reflect changes in the GH-IGF-I axis (24 -27) . However, an irreversible sex difference in GH secretory patterns develops soon after birth (24, 28) , and this may influence the nature of E effects in males and females. In addition, the association between E effects on the GH-IGF-I axis and E effects on growth and metabolism has not been rigorously analyzed in either male or female rats. Specifically, correlation/regression analyses of data sets of individual rats have not been reported. Thus, it is unclear if measures of growth or metabolism in a given rat during E treatment are significantly related to the GH or IGF-I levels in that rat.
To address the above considerations, male rats were used 1) to study the role of T 3 in E and SERM effects and their relation to GH and IGF-I, and 2) to evaluate the therapeutic potential of SERMs in androgen-deprived males. The results show that interplay with T 3 contributes to multiple E actions in male rats and imply that SERMs may benefit men on androgen deprivation therapy. In addition, the correlation/ regression analyses suggest novel roles for GH and IGF-I in E effects on specific parameters. Finally, the data revealed three pharmacologically distinct classes of E responses that presumably reflect the diversity of ER effector mechanisms in vivo.
Materials and Methods Animals
All protocols followed NIH guidelines on the use and care of animals and were approved by the institutional Animal Care and Use Committee. Forty-eight young adult male Sprague Dawley rats were used (Taconic Farms, Inc., Germantown, PA); rats were 75-80 d old and weighed 350 -375 g upon arrival. Forty-four of the rats were given 0.03% methimazole (a thioamide inhibitor of thyroid hormone synthesis) in drinking water throughout the study to induce hypothyroidism and allow experimental control of T 3 levels. Calcium chloride (1%) was included with methimazole in the water to ensure adequate dietary calcium intake because hypothyroidism decreases food intake by up to 40% (14) . Methimazole evoked functional hypothyroidism in all rats within 14 d based on loss of normal weight gain. Rats were then orchidectomized under halothane-O 2 anesthesia, and experimental treatments started 3 d after surgery (when rats were 92-97 d old). Four rats were not treated with methimazole and were subjected only to sham-surgery to provide euthyroid, testis-intact controls. During the study, one hypothyroid rat died from complications of anesthesia, and one died from spinal cord trauma due to an injection accident. Thus, data were obtained from 42 orchidectomized-hypothyroid rats and 4 euthyroid, testis-intact rats.
It should be noted that the male rats used in this study had ages similar to those of female rats used in previous studies of T 3 interactions. Both male and female rats still have active epiphyseal growth plates in the age range studied, unlike the bones of adult men and women or aged adult rats. Nonetheless, young adult rats respond to gonadectomy and E or SERM treatment with robust changes in cancellous bone turnover and BMD that are qualitatively similar to those of aged rats with closed epiphyses (29, 30) .
Experimental design and drug treatments
A gonadectomized, hypothyroid rat model was used which allows TM, E2B, and T 3 effects to be separately identified and hormonal interactions studied. The model was designed to selectively detect E2B and TM effects on the pharmacodynamic actions of T 3 and avoid other types of hormonal interactions. Thus, use of methimazole eliminates changes in the synthesis or release of T 3 or T 4 as a mechanism of E2B or TM effects. Use of T 3 eliminates interactions related to 5Ј-deiodination of T 4 to T 3 . Use of T 3 also avoids interactions due to E2B or TM effects on plasma T 4 -binding proteins (transthyretin and T 4 -binding globulin). T 3 has only 1/10 the affinity of T 4 for such proteins, and unlike T 4 , the distribution of T 3 in the rat is not restricted by plasma protein binding (volume of distribution ϭ 1.65 liter/kg for T 3 vs. 0.16 liter/kg for T 4 ) (31) .
Six groups of orchidectomized rats received the following drug and hormone treatments starting 3 d after surgery: 1) vehicle solutions alone (n ϭ 8); 2) TM (trans isomer, free base) at 0.5 mg/kg via sc injection, once daily (n ϭ 7); 3) 17␤-E2-3-benzoate (E2B) at 50 g/kg via sc injection three times weekly (n ϭ 6); 4) T 3 (sodium salt) at 10 g/kg via ip injection once daily (n ϭ 7); 5) T 3 plus TM (n ϭ 7); and 6) T 3 plus E2B (n ϭ 8). The group of four euthyroid, testis-intact rats received daily injections of vehicle solutions. During the treatment phase of the study, body weight was measured three times per week and food intake was measured once a week. Rats were gang-caged (3-4 per cage) to decrease risk of hypothermia due to hypothyroidism; thus, total food intake per group was measured during a 24-h period, and average intake per rat interpolated. Body temperature was measured weekly with a rectal thermocouple probe and digital thermometer to provide an index of T 3 effects on thermogenesis.
The doses of E2B, TM, and T 3 used in this study have been found to yield maximal target organ and growth responses in dose-response studies in ovariectomized or ovariectomized, hypothyroid female rats (15, 32) . E2B and TM were dissolved in sesame oil with 2% benzyl alcohol; T 3 was dissolved in 0.9% NaCl with 5 mm NaOH.
Tissue processing
After 6 wk of treatment, rats were euthanized in random order with 100 mg/kg sodium pentobarbital (ip) between 1030 and 1530 h. Blood, anterior pituitaries, and right tibias were collected within 5 min of pentobarbital injection as previously described (14, 15) . Blood samples were allowed to clot for 5 min at room temperature, cooled on ice, and then refrigerated at 5 C; serum was collected the next day, aliquoted, and stored at Ϫ80 C until assay. The right tibia was stripped of most muscle and connective tissue and stored in 70% ethanol for subsequent measurements of tibia length (an index of longitudinal growth) and bone mineral density (BMD). Anterior pituitaries were sonicated in 400 l of 10 mm sodium phosphate buffer (pH 7.5) containing 150 mm NaCl and 0.1% Triton X-100; samples were then aliquoted and stored at Ϫ20 C until assay. Seminal vesicles were dissected and weighed. The ventral prostate lobes were visually inspected for any gross differences in size. The left kidney and heart were dissected and weighed to examine the effect of TM or E2B on T 3 actions that yield increases in heart and kidney mass that exceed changes in overall somatic growth (33, 34) .
Analysis of BMD
Tibia BMD was measured by dual-energy x-ray absorptiometry with a QDR-1000 (Hologic, Inc., Waltham, MA) as previously described (14, 15) . Image analysis software (Hologic, Inc.) automatically calculated bone mineral content (g), cross-sectional area (cm 2 ), and BMD (g/cm 2 ) in two regions: the proximal tibia and the diaphysis. The proximal tibia (upper 1/3 of tibia length) is relatively enriched in cancellous bone and has a higher ratio of cancellous to cortical bone than the diaphysis (middle 1/3 of tibia length) (35) .
Metabolic analyses
Lipid metabolism was assessed by measuring total cholesterol, triglycerides, and ␤-hydroxybutyrate (an index of fatty acid ␤-oxidation) in serum using colorimetric kits from Sigma (St. Louis, MO). Serum glucose was measured as an index of carbohydrate metabolism using a colorimetric kit from Stanbio Laboratories (San Antonio, TX). In the rat, 70 -80% of serum cholesterol is bound to high-density lipoprotein, and estrogens and SERMs have equivalent effects on high density lipoprotein-or low density lipoprotein-cholesterol (36) .
Assay of serum GH and IGF-I
Serum levels of GH and IGF-I were used to assess changes in the GH-IGF-I axis. Total serum levels of IGF-I were determined using a RIA kit from Nichols Institute Diagnostics (San Juan Capistrano, CA) after extraction of IGF-I from serum. IGF-I in rat serum was separated from IGF-binding proteins using the acid-ethanol extraction method described by Crawford et al. (37) . Serum samples (100 l) were mixed with 900 l acid-ethanol solution (12.5% 2 m HCl: 87.5% ethanol, vol/vol) and incubated 30 min at room temperature. Following centrifugation at 1,500 ϫ g for 30 min at 5 C, 200 l of the supernate was mixed with 100 l 0.855 m Tris base (pH 11) and incubated 30 min at room temperature. After centrifugation at 1,500 ϫ g for 30 min (5 C), 100 l of the final supernate was mixed with 1.4 ml phosphate buffer (pH 7.5), and used for RIA. This acid-ethanol extraction method has previously been validated for RIA of total IGF-I in male and female rat serum by comparison with results using HPLC methodology (37) . Serum GH was determined using a rat GH RIA kit from Amersham Pharmacia Biotech (Piscataway, NJ).
Anterior pituitary analyses
Induction of anterior pituitary PRL and GH by E and T 3 , respectively, was qualitatively analyzed using denaturing PAGE as previously described (15, 16) . Such analyses have previously been validated with GH and PRL RIAs (15, 16) . Anterior pituitary levels of glandular kallikrein (an E-induced protease in lactotrophs) was assayed using d-Val-LeuArg-p-nitroanilide as previously described (38) . Total protein provided an index of E-induced anterior pituitary hyperplasia (38) .
Statistical analysis of grouped data
Data were subjected to ANOVA followed by a posthoc analysis with Duncan's new multiple range test; P Ͻ 0.05 was the criterion of significance. Serum GH and triglyceride data values were log-transformed to normalize variances.
The change in a parameter due to T 3 ('⌬ due to T 3 Ј) was calculated by subtracting the mean of the vehicle, TM, or E2B group without T 3 from each data point in the matching group with T 3 ; transformed data were then analyzed as noted above. This facilitated comparison of E2B and TM interplay with T 3 in diverse parameters and was used to calculate the % efficacy of TM relative to E2B (100%) in responses involving interplay with T 3 .
Correlation/regression analysis
Pearson's product-moment correlation (r) and multiple linear regression analysis was used to identify significant associations of serum GH or IGF-I to other parameters. Correlations/regressions were calculated using sets of individual rat data (single units of expression) that captured the effects of the four distinct hormonal manipulations studied (T 3 manipulation with and without an estrogenic background, and estrogenic manipulation with and without a T 3 background). Correlations capturing the effect of T 3 manipulation without an estrogenic background were calculated using individual rat data from groups 1 (vehicle alone) and 4 (T 3 alone) (n ϭ 15 data pairs per parameter). Correlations during T 3 manipulation with an estrogenic background used data from groups 2 (TM alone), 3 (E2B alone), 5(T 3 plus TM) and 6 (T 3 plus E2B) (n ϭ 27). Correlations during estrogenic manipulation without T 3 used data from groups 1 (vehicle alone), 2 (TM alone), and 3 (E2B alone) (n ϭ 21). Correlations during estrogenic manipulation in the presence of T 3 used data from groups 4 (T 3 alone), 5 (TM plus T 3 ) and 6 (E2B plus T 3 ) (n ϭ 21).
Results

TM, E2B, and T 3 effects on tibia BMD
BMD of the proximal tibia (enriched in cancellous bone) was 9% lower in orchidectomized, hypothyroid controls than in euthyroid, testis-intact rats (Fig. 1 ). This probably reflects the lack of testicular androgens (39 -42) . T 3 alone had no effect on BMD but potentiated TM and E2B effects: TM evoked 4.2% increases in rats lacking T 3 , and 9.8% increases in rats given T 3 . E2B evoked 12.8% and 17.6% increases in BMD in the absence or presence of T 3 , respectively. In T 3 -treated rats, TM prevented bone loss associated with orchidectomy, while E2B yielded BMD values exceeding euthyroid, testis-intact rats ( Fig. 1) .
TM had 1/3 the efficacy of E2B in rats lacking T 3 , but BMD increases due to T 3 interplay with TM and E2B were equivalent (see inset, Fig. 1 ). This suggests that E effects on BMD in male rats involved a T 3 -independent component in which TM had low efficacy, and a T 3 -dependent component in which TM and E2B had equivalent efficacy.
It is of note that rats lacking T 3 displayed no net growth (see Fig. 3 ), and E2B increased proximal tibia BMD in such rats without altering tibia length (see Fig. 4 ) or cross-sectional area (not shown). E2B effects on BMD were thus largely independent of changes in bone growth.
Tibia diaphysis BMD did not significantly differ among groups (Fig. 1) . The diaphysis has a lower ratio of cancellous bone to cortical bone, and the data are consistent with dif- ferences in the turnover rates and E sensitivity of cancellous bone and cortical bone (29, 30, 35) .
TM, E2B, and T 3 effects on serum levels of cholesterol and triglycerides
TM lowered cholesterol by 38 mg/dl in orchidectomized, hypothyroid rats lacking T 3 (Fig. 2) . Cholesterol was also reduced by T 3 (Ϫ24 mg/dl), and T 3 and TM effects were additive. Thus, TM and T 3 affect cholesterol independently of one another. Remarkably, E2B had no effect on cholesterol, even at doses as high as 250 g/kg (unpublished data). Euthyroid, testis-intact male rats had slightly lower cholesterol levels (Ϫ18 mg/dl) than orchidectomized, hypothyroid rats treated with T 3 , but the difference was not significant (Fig. 2) .
Serum triglycerides in intact rats were over twice that of orchidectomized, hypothyroid controls (Fig. 2) . T 3 , TM, or E2B alone did not alter triglycerides in hypothyroid rats, although TM tended to lower levels. However, TM and E2B increased triglycerides in T 3 -treated rats (Fig. 2) ; the TM increase was 65% that evoked by E2B (inset, Fig. 2 ).
TM, E2B, and T 3 effects on male sex organs
TM had no effect on seminal vesicle weight in orchidectomized, hypothyroid rats with or without T 3 (Fig. 2) ; this was also the case with the ventral prostate (based on visual inspection). E2B in combination with T 3 evoked a small rise in seminal vesicle weight (Fig. 2) , but seminal vesicles in rats given E2B plus T 3 were still minuscule compared with testisintact rats.
TM, E2B, and T 3 effects on somatic growth
In the first 10 d, orchidectomized, hypothyroid controls lost 3% of body weight while E2B-or TM-treated rats lost 9% (Fig. 3) . Weight then stabilized in control and TM-treated rats, but a slow weight loss continued in E2B-treated rats (Ϫ4% in 32 d) (Fig. 3) . T 3 increased weight, and this gain was inhibited 78% by TM and 65% by E2B (inset, Fig. 3 ).
In rats lacking T 3 , TM or E2B did not alter tibia length. However, increases in tibia length evoked by T 3 were similarly inhibited by TM (Ϫ69%) and E2B (Ϫ81%) (inset, Fig. 4 ).
During the 6-wk treatment phase of the study, euthyroid, testis-intact rats gained 70% more weight than orchidectomized, hypothyroid rats treated with T 3 alone (not shown). This presumably reflects a stimulation of somatic growth by testicular androgens (43) , which may also partly account for the greater tibia lengths of testis-intact rats (Fig. 4) .
TM, E2B, and T 3 effects on serum and pituitary GH
Serum GH in orchidectomized, hypothyroid rats was only 8% that of euthyroid, testis-intact rats (Fig. 4) , and this was associated with a loss of pituitary GH content (Fig. 5 ). Although T 3 alone increased serum GH, it yielded only 25% the level of euthyroid, testis-intact males even though pituitary GH content was almost fully restored. In rats lacking T 3 , TM and E2B evoked 4.0-fold and 6.9-fold increases in serum GH, respectively, whereas T 3 alone yielded a 3.2-fold increase (Fig. 4) . However, TM and E2B evoked only weak T 3 -like effects on pituitary GH content (Fig. 5) . Thus, TM and E2B effects on serum GH do not simply reflect changes in pituitary GH content; alterations in neuroendocrine regulation are evident.
TM and E2B effects on serum GH were enhanced by T 3 and yielded increases greater than expected from an additive interaction with T 3 (inset, Fig. 4) . In either the presence or absence of T 3 , TM displayed half the efficacy of E2B on serum GH. On the other hand, T 3 induction of pituitary GH content was clearly inhibited by TM, whereas E2B had little effect (Fig. 5) . Thus, although TM mimicked E2B effects on serum GH in T 3 -treated rats, it displayed a distinct effect on pituitary GH. The pituitary GH data of male rats match the results of similar studies in female rats (14 -17) . TM or E2B effects to increase serum GH, however, were much smaller in female rats, and were not enhanced by T 3 (15) .
Only orchidectomized, hypothyroid rats given T 3 in combination with TM or E2B had serum GH levels approaching those of euthyroid, testis-intact males. However, serum GH increases evoked by E2B and TM did not yield corresponding increases in somatic growth.
TM, E2B, and T 3 effects on serum IGF-I
Orchidectomized, hypothyroid rats had serum IGF-I levels that were half that of testis-intact, euthyroid rats (Fig. 4) . T 3 alone fully restored IGF-1 to the levels of euthyroid, testisintact rats despite its relatively modest effect on serum GH. In contrast, E2B or TM did not yield IGF-I increases similar to T 3 even though they caused greater increases in serum GH. Interestingly, E2B and TM had differing effects on IGF-I in the absence of T 3 ; TM modestly increased IGF-I (ϩ20%), whereas E2B markedly lowered IGF-I (Ϫ40%) (Fig. 4) . 
Rats treated with E2B plus T 3 also had much lower IGF-I levels than those given T 3 alone, due in large part to a smaller IGF-I response to T 3 . TM also displayed a tendency to lower IGF-I in T 3 -treated rats (Ϫ12%) that did not reach significance. However, unlike E2B, TM alone modestly increased IGF-I (ϩ20%), and this partly masked inhibition of T 3 effects. When IGF-I increases due to T 3 were calculated, it was evident that this T 3 effect was significantly inhibited by TM (Ϫ42%) as well as by E2B (Ϫ73%) (inset, Fig. 4) . TM effects on IGF-I in male rats resemble results in female rats (14) : this includes both TM's tendency to increase IGF-I in the absence of T 3 , and the inhibition of T 3 effects on IGF-I.
Effects on food intake, body temperature, serum glucose, and serum ␤-hydroxybutyrate
Orchidectomized, hypothyroid male rats lacking T 3 consumed 35% less food per kg body weight than euthyroid, testis-intact males (Fig. 7) . T 3 increased food intake to that of euthyroid, testis-intact rats. E2B and TM did not alter food intake in rats with or without T 3 (inset, Fig. 7 ). TM and E2B effects on growth and metabolism are unlikely to reflect changes in food intake. The data further document that not all T 3 effects are sensitive to E2B or TM.
Body temperature was unaffected by TM or E2B in the absence of T 3 (Fig. 7) . T 3 produced a 1.5 C increase in temperatures of orchidectomized, hypothyroid rats. T 3 effects on body temperature were slightly inhibited by TM and E2B (Ϫ11% and Ϫ33%, respectively), but only E2B had a significant effect. Only a small fraction of the thermogenic effects of T 3 are sensitive to E2B, and TM has only 1/3 the efficacy of E2B.
Euthyroid, testis-intact rats had significantly lower body temperatures (Ϫ1.0 C) than orchidectomized, hypothyroid rats given T 3 (Fig. 7) . This temperature difference is due to testicular androgens; it does not reflect use of an excessive T 3 dose (our manuscript in preparation).
TM and E2B tended to lower serum glucose in orchidectomized, hypothyroid rats lacking T 3 , but the changes were insignificant (Fig. 7) . T 3 alone had no effect on glucose but enhanced TM and E2B effects over 2-fold. Decreases in glucose evoked by E2B (Ϫ28%) were significant in T 3 -treated rats, but not those for TM (Ϫ13%). Serum ␤-hydroxybutyrate levels were less than 2.5 mg/dl in all groups (data not shown); thus, no major treatment effects on fatty acid oxidation were evident. The glucose and ␤-hydroxybutyrate data did not reveal alterations in energy metabolism likely to explain E2B and TM effects on growth.
TM, E2B, and T 3 effects on relative heart and kidney weights
Calculation of organ weight relative to body weight (relative weight, g/kg) can detect changes in organ weight that are disproportionate from changes in body weight. T 3 significantly increased relative heart weight in hypothyroid male rats (Fig. 8) ; this may reflect direct actions on the heart as well as effects secondary to changes in vascular tone and autonomic nervous system function (33) . TM and E2B did not alter relative heart weight in rats lacking T 3 , and increases evoked by T 3 were insensitive to E2B or TM (inset, Fig. 8 ). Relative kidney weight was slightly increased by TM or E2B in rats lacking T 3 (ϩ0.5 and ϩ0.4 g/kg, respectively). T 3 caused greater increases (ϩ1.2 g/kg). T 3 and TM had additive effects on relative kidney weight, but increases with E2B plus T 3 were larger than expected (inset, Fig. 8) .
TM, E2B, and T 3 effects on the anterior pituitary
Total pituitary protein content is well correlated with pituitary weight and provides a useful index of E-evoked pituitary hyperplasia in the rat (38, 44) . E2B or T 3 alone caused only modest protein increases, but synergized with one another to evoke striking increases (Fig. 6 ). Unlike E2B, TM slightly decreased pituitary protein in the presence or absence of T 3 .
E2B selectively induced pituitary PRL in rats lacking T 3 (Fig. 5) . T 3 alone evoked only small PRL increases, but markedly enhanced E2B actions. However, PRL increases with E2B plus T 3 were coupled to nonspecific increases pituitary proteins characteristic of tissue hyperplasia (Figs. 5 and 6 ). TM did not alter PRL either with or without T 3 .
T 3 alone slightly decreased glandular kallikrein (Fig. 6) , an E-induced lactotroph protease (32) . E2B induced total kallikrein activity (nmol/min⅐pituitary) by 6-fold in the absence of T 3 , and 18-fold in the presence of T 3 . However, E2B induction of kallikrein was unaffected by T 3 when expressed as specific activity (nmol/min⅐mg protein) to adjust for changes in total protein due to tissue hyperplasia (Fig. 6) . TM lacked effect on glandular kallikrein.
Overall, the data indicate that E2B induction of PRL and kallikrein was T 3 independent, whereas E2B actions to evoke pituitary hyperplasia were T 3 dependent. The hyperplastic effect of E is due to a selective induction of lactotroph proliferation (45, 46) , and this amplifies E2B effects on PRL and kallikrein by increasing lactotroph numbers.
Correlation of serum GH and serum IGF-I with other physiological parameters
Group means suggested that E2B and TM effects on GH and IGF-I may be related to changes in four other parameters: ⌬ body weight, tibia length, proximal tibia BMD and serum triglycerides. Correlation/regression analysis was used to quantitatively assess these associations.
E2B and TM effects on a parameter might reflect changes in T 3 regulation of GH or IGF-I, changes in GH or IGF-I independent of T 3 , effects unrelated to GH or IGF-I, or combinations thereof. To separately evaluate these alternatives, correlation analysis was performed on four unstructured sets of individual rat data capturing the relationships associated with T 3 manipulations with or without an estrogenic background (E2B or TM treatment), and estrogenic manipulations with or without a T 3 background (see Materials and Methods for details). Relative heart weight illustrates results for a parameter that was unaffected by E2B or TM and was unlikely to be related to GH or IGF-I. Relative heart weights during T 3 manipulation in the absence of E2B/TM were strongly correlated with GH and IGF-I, but these correlations were absent from T 3 manipulations with E2B/TM ( Table 1) . Because E2B or TM altered GH and IGF-I without affecting relative heart weight (Figs. 4 and 7) , the correlations during T 3 manipu- Pearson's correlation coefficients (r) were calculated using data pairs from individual rats in the groups relevant to the indicated hormonal manipulation and hormonal background (see text for details); r values needed for significance vary depending on the number of data pairs (n) analyzed.
a P Ͻ 0.05. b P Ͻ 0.01. lation without E2B/TM must be coincidental. Indeed, heart weight was not significantly correlated with GH or IGF-I in estrogenic manipulations (Table 1) . GH correlations with IGF-I illustrate results obtained with parameters known to be functionally related in vivo. During T 3 manipulation, GH exhibited a significant positive correlation with IGF-I in the absence of E2B/TM, but not in the presence of E2B/TM (Table 1) . Thus, an estrogenic background impaired GH induction of IGF-I during T 3 manipulation, as expected from the grouped results (Fig. 4, inset) . GH and IGF-I were poorly related during estrogenic manipulations without T 3 , but a surprising negative correlation was seen during estrogenic manipulation of T 3 -treated rats (Table  1) . This inverse relation suggests the operation of an IGF-I negative feedback loop that inhibits GH release and is T 3 dependent. These results suggest that decreases in IGF-I (or reduced sensitivity of the feedback loop to IGF-I) may contribute to E2B and TM effects on GH in T 3 -treated rats.
Body weight change during T 3 manipulation without E2B or TM was positively correlated with GH and IGF-I (Table 1) . E2B and TM degraded such correlations during T 3 manipulation; this suggests that a portion of E2B/TM effects on body weight involve T 3 actions unrelated to changes in GH and IGF-I levels per se (see below). On the other hand, weight change in estrogenic manipulations was positively correlated with IGF-I and negatively correlated with GH regardless of T 3 background. Given the essential role of IGF-I in growth (25) , the results suggest that IGF-I decreases also partly contribute to E effects on weight.
Tibia length was not correlated with GH during T 3 manipulation without E2B/TM but displayed a strong positive correlation with IGF-I ( Table 1 ). This IGF-I correlation was obliterated in the presence of E2B/TM. Thus, changes in serum IGF-I poorly explain E2B and TM effects on T 3 -evoked bone growth; effects on other T 3 actions that promote bone growth seem likely. This might include T 3 actions to enhance tissue sensitivity to IGF-I because hypothyroidism eliminated growth but lowered IGF-I only 50% (see Figs. 3 and 4) . On the other hand, tibia length was positively correlated with IGF-I and negatively correlated with GH during estrogenic manipulations in the presence of T 3 , but not in its absence. Given the role of IGF-I in longitudinal bone growth (25) , this suggests that decreases in IGF-I may also contribute to E2B and TM effects on tibia length. It is also noteworthy that, unlike body weight change, tibia length displayed an association with IGF-I and GH only in the presence of T 3 .
Proximal tibia BMD was positively correlated with serum GH during T 3 manipulations in the presence of E2B or TM, but not in their absence. The BMD and GH correlation was even stronger in estrogenic manipulations, and T 3 had little influence on the association. Unlike body weight or tibia length, BMD was not significantly correlated with IGF-I during T 3 manipulations, and BMD was negatively correlated with IGF-I during estrogenic manipulations regardless of T 3 . In view of evidence that GH can increase BMD (47), the correlation analyses suggest that E2B and TM effects on BMD may partly reflect their effects on serum GH.
Triglycerides displayed a significant positive correlation with GH only during T 3 manipulations in the presence of E2B/TM. Triglycerides and IGF-I were poorly associated during T 3 manipulations. Triglycerides were also significantly correlated with GH (positive) and IGF-I (negative) during estrogenic manipulations with T 3 , but not in its absence. In view of evidence that GH can increase triglycerides (48, 49) , the results suggest that GH may contribute to E2B and TM effects on triglycerides. Unlike BMD, the triglyceride response to E2B and TM displayed a T 3 requirement that appears unrelated to effects on GH and IGF-I.
Multiple linear regression analysis
During estrogenic manipulations with T 3 , serum GH and IGF-I were inversely related, and it wasn't surprising that GH and IGF-I correlations with a parameter were often the inverse of one another. However, GH and IGF-I were not correlated during estrogenic manipulations without T 3 ; thus, it was notable that in such manipulations BMD was positively correlated with GH and negatively correlated with IGF-I, whereas the opposite occurred with body weight change ( Table 1 ). This suggested that GH and IGF-I may independently contribute to E effects on BMD and body weight. Multiple linear regression analysis was used to evaluate this possibility.
Multiple linear regression analysis can be used to test hypotheses that two or more independent variables (GH and IGF-I in this case) make significant, independent contributions to regressions predicting the observed levels of a dependent variable (BMD, etc.). This involves fitting a regression equation to the data using the method of least-squares. The residual sum squares (total, regression, and error) are then used to determine the significance of the regression coefficients contributed by each independent variable (null hypothesis: coefficients ϭ 0), and the regression correlation coefficient (r). For the present analysis, the significance of the regression coefficient of each independent variable was of primary interest.
Proximal tibia BMD was the only parameter where GH and IGF-I both made significant, independent contributions to regressions predicting observed values. In estrogenic manipulations without T 3 , BMD was well correlated (r ϭ 0.78; P Ͻ 0.01) with regression predictions [BMD ϭ 0.258 ϩ 0.0242(logGH) Ϫ 0.000064(IGF-I)], and the regression coefficients for GH and IGF-I were each significant (P Ͻ 0.01). In estrogenic manipulations with T 3 , BMD displayed an r ϭ 0.71 (P Ͻ 0.01) with regression predictions [BMD ϭ 0.270 ϩ 0.0172(logGH) Ϫ 0.0000373(IGF-I)]; the IGF-I coefficient was significant (P ϭ 0.04) and the GH coefficient neared significance (P ϭ 0.067). Regression predictions from analysis of all orchidectomized rat data [BMD ϭ 0.239 ϩ 0.0271(logGH) Ϫ (0.0000234 ϫ IGF-I)] yielded an r ϭ 0.72 (P Ͻ 0.01), with significant regression coefficients for both GH (P Ͻ 0.01) and IGF-I (P ϭ 0.02).
Discussion
Selective metabolic effects of tamoxifen in male rats
Elderly men are often intolerant or poorly responsive to drugs commonly used to prevent osteoporosis or lower cholesterol, and may benefit from alternative therapies. SERMs selectively mimic metabolic effects of estrogens on bone and low density lipoprotein cholesterol in postmenopausal women (50 -54) and might evoke such metabolic benefits in men without risk of feminization. In orchidectomizedhypothyroid rats treated with T 3 in this study, TM prevented BMD decreases associated with orchidectomy, and lowered blood cholesterol. Moreover, TM lacked androgenic effects on seminal vesicle or prostate growth. Euthyroid male rats have yielded equivalent findings (our manuscript in preparation). Ovariectomized female rats similar in age to the males of this study have usefully modeled E effects on bone in postmenopausal women (29, 30) , and the present results may have corresponding relevance for androgen-deprived men. Studies of TM in androgen-deprived men should soon address this issue.
Influence of T 3 on E2B and tamoxifen effects, and relation to the GH-IGF-I axis
The hypothyroid, gonadectomized rat model enables the detection of target-selective T 3 and E interplay arising from pharmacodynamic (receptor-mediated) mechanisms (14 -17) . The present data further indicate that some actions of E2B and TM involve interplay with T 3 and also imply some sex differences. Moreover, correlation analysis provided a rigorous test of the association of serum GH and IGF-I with specific E responses in individual rats. The significant correlations found in data sets capturing the effects of estrogenic manipulation do not prove a cause and effect linkage. Nonetheless, the significant correlations satisfy an essential requirement of hypotheses that changes in GH and IGF-I contribute to E effects on growth and metabolism, and also imply distinct roles for GH and IGF-I in different E responses.
Interactions related to the GH-IGF-I axis and somatic growth
The GH-IGF-I axis has a major role in growth and metabolism (25, 27, 47, 55) , and is a likely target of E and T 3 interplay. T 3 promotes GH synthesis and secretion, enhances GH induction of hepatic IGF-I synthesis, and induces IGF-I receptors and binding proteins (56 -58) . Estrogens and TM also increase GH secretion but lower serum IGF-I as well as hepatic expression of IGF-I mRNA (26, 59 -65) .
In the present study, increases in serum GH evoked by T 3 were coupled to significant increases in IGF-I. In contrast, TM or E2B failed to increase IGF-I despite striking effects to increase GH. Interestingly, estrogen effects on serum IGF-I appear to involve two components. A T 3 -independent component was evident in E2B effects to lower IGF-I by 40% in rats lacking T 3 ; TM lacked agonist efficacy in this component and slightly raised IGF-I. A T 3 -dependent component was evident in E2B and TM inhibition of T 3 induction of IGF-I; TM had 58% the efficacy of E2B in this component. These data are consistent with findings in hypothyroid female rats (14) in which TM slightly elevated IGF-I in rats lacking T 3 , but inhibited T 3 effects on IGF-I. It should be noted that TM did not inhibit ovine GH effects on somatic growth or IGF-I in hypothyroid rats (14) , nor do estrogens consistently inhibit GH effects on serum IGF-I or hepatic IGF-I mRNA in hypophysectomized rats (61, 62) . Overall, E effects on serum IGF-I are complex and seem likely to target T 3 actions that enhance GH effects, as well as mechanisms independent of T 3 or GH.
Multiple mechanisms also seem to mediate E effects on T 3 -evoked growth. Weight gain and tibia length were correlated with IGF-I during estrogenic manipulations, suggesting that decreases in IGF-I contribute to E2B and TM effects to inhibit growth. In T 3 -treated rats, the net decrease in IGF-I caused by E2B (Ϫ55%) seemed large enough to impair growth, but the 12% decrease with TM was unlikely to do so. This might indicate that IGF-I production in targets such as bone is more relevant to E2B and TM effects on growth (66, 67) . Alternatively, decreases in tissue sensitivity to IGF-I due to E effects on IGF-I receptors or binding proteins may contribute to the inhibition of somatic growth (63) (64) (65) . Indeed, IGF-I feedback inhibits GH release (68, 69) , and TM effects on serum GH in T 3 -treated rats seem consistent with reduced sensitivity of the feedback mechanism to IGF-I. Decreases in IGF-I sensitivity may also be relevant to E2B and TM effects to degrade the correlation of body weight change and tibia length with serum GH and IGF-I during T 3 manipulations.
Interactions related to BMD
In ovariectomized-hypothyroid female rats, T 3 decreased proximal tibia BMD, and E2B and TM effects seemed to reflect inhibition of T 3 actions (14, 15) . This appeared consistent with T 3 actions directly on bone to stimulate resorption (70, 71) , the increased risk of osteoporosis due to thyrotoxicosis (72, 73) , and E prevention of T 4 -evoked bone loss in postmenopausal women (74, 75) . Nonetheless, T 3 alone lacked effect on BMD in the present male rats, and E2B increased BMD in the absence of T 3 . This suggests a sex difference in T 3 effects on BMD; direct comparisons of the sexes are needed to clarify this issue.
TM had less effect on BMD than E2B in the present male rats, but TM has been shown to fully mimic E effects on BMD in female rats (76, 77) , again hinting at a sex difference. In this regard, it is of note that E effects on BMD seemed to involve two components; TM had efficacy equal to E2B in a T 3 -dependent component but only 33% efficacy in a T 3 -independent component. Given the T 3 -dependence of E effects on BMD in female rats (14) , the T 3 -independent component may be most relevant to any sex differences.
GH stimulates bone remodeling associated with longitudinal growth and also participates in the remodeling of mature bone (47) . Although GH stimulates both bone resorption and formation, an anabolic effect eventually emerges due to greater bone formation. In the present study, BMD was positively correlated with serum GH during estrogenic manipulations in either the presence or absence of T 3 ; such results suggest that GH increases contribute to E2B and TM effects on BMD. This association is unlikely to reflect changes in growth-related bone remodeling since somatic growth was absent in rats lacking T 3 . Given the sex difference in GH secretion patterns (see Introduction), GH might also be relevant to possible sex differences in T 3 and E effects on BMD. Nonetheless, it is important to note that GH release evoked by T 3 alone failed to increase BMD in this and other studies of hypothyroid, gonadectomized rats (14, 15) . This may be relevant to evidence that E can act directly on bone to alter remodeling (1, 78) ; such actions may enhance the net anabolic effect of GH. Indeed, TM enhanced ovine GH effects on BMD in hypothyroid rats (14) , and transgenic mice overexpressing human GH require ovarian estrogens to develop elevated BMD (79) .
BMD was also negatively correlated with IGF-I during estrogenic manipulations. Bone growth and remodeling involves a complex interplay between T 3 , GH, IGF-I as well as other hormones and cytokines, and is not fully understood (27, 47, 78) . Many GH effects result from IGF-I released from the liver or target tissue (the somatomedin theory of GH action). However, effector mechanisms unrelated to IGF-I also contribute in some tissues, including bone (the dualeffector theory of GH action) (47, 80, 81) . An implication of the dual-effector theory is that GH and IGF-I may make distinct contributions to GH responses involving dual effectors. Indeed, multiple linear regression analysis showed that GH and IGF-I each made significant, independent contributions to regression equations predicting BMD during estrogenic manipulations; this was true of no other physiological parameters. This result appears to satisfy a major requirement of the hypothesis that GH actions via multiple effector mechanisms (IGF-I dependent and independent) may be relevant to E effects on BMD.
Interactions related to serum triglycerides and cholesterol
Estrogens and SERMs can increase serum triglycerides in rats and man (50, 54, 82, 83) . In the male rats used in this study, such increases were T 3 dependent, and TM had 65% the efficacy of E2B; female rats gave similar results (14, 15, 17) . Moreover, triglycerides were positively correlated with GH during estrogenic manipulations in T 3 -treated rats. This may be relevant to reports that GH can stimulate the hepatic synthesis or release of triglycerides (48, 49) . Although T 3 alone had little effect on triglycerides, it is well known to stimulate multiple pathways involved in fatty acid and triglyceride synthesis, storage, mobilization, and oxidation. E interplay with a subset of such T 3 actions might alter the balance between opposing pathways to increase triglycerides.
The role of T 3 in E and SERM effects on serum cholesterol had not been previously studied. TM evoked cholesterol decreases that were T 3 independent, but E2B had no effect despite powerful actions on other parameters in the same rats. Others have reported similar findings. Thus, ethinyl E2 and SERMs lowered cholesterol at doses affecting the uterus, somatic growth and bone metabolism, but 17␤-E2 had no effect on cholesterol at doses evoking maximal effects on other targets (36, 84) . Moreover, this phenomenon is not dependent on the route of drug dosing (36) . Classic estrogens such as 17␤-E2, E2B, and ethinyl E2 have been thought to have equivalent pharmacodynamic actions despite differing pharmacokinetics, and act as potent agonists in most T 3 -independent E responses. However, the cholesterol response reveals a more complex pharmacology and defines a novel T 3 -independent E response. LH suppression in ovariectomized rats is another unusual T 3 -independent response because E2B and TM exhibit similar agonist efficacy (15) .
Interactions related to lactotroph hyperplasia
Pituitary hyperplasia evoked by E2B represents another distinct E response: it was T 3 dependent, but TM lacked agonist efficacy (unlike other T 3 -dependent responses). E2B and T 3 interplay to evoke cell proliferation is tissue-specific since induction of uterine growth does not require T 3 (15) . The interplay is also gene specific because PRL and kallikrein induction in lactotrophs was largely T 3 -independent.
Pharmacological classification of in vivo E responses
E2 binding to ER␣ or ER␤ is now recognized to trigger a cascade of interactions among diverse effector molecules that ultimately evoke an E response. It is also evident that SERMs can activate ER effector mechanisms mediating some responses, while inhibiting those mediating other responses (see Refs. 4 -6 for review). This differential sensitivity of ER effector mechanisms is widely recognized to provide the molecular foundation for the disparate pharmacological characteristics of different E responses. However, the pharmacological features of different in vivo E responses have not been systematically analyzed, and it's unclear how many pharmacologically distinct classes are operative in animals and man. Such information may identify groups of in vivo E responses mediated by similar effector mechanisms, and indicate how many distinct effector mechanisms regulate physiological systems in vivo. Also, as ER ligands become available that target selective ER subtypes or effectors, it may be possible to link the pharmacological classes to specific ER effector mechanisms. Conversely, classification efforts may identify sets of in vivo E responses amenable to selective pharmacological targeting, and thus facilitate efforts to design new ER ligands with novel therapeutic actions.
Based on the present results and prior reports (16, 17, 36, 76, 77, 84) , three pharmacologically distinct classes of in vivo E responses can currently be identified in the rat (Classes A, B, and C) ( Table 2 ). In Class A responses, classic estrogens (E2B, 17␤-E2, ethinyl E2) act as potent agonists, and TM acts more like an antagonist (Ͻ33% agonist efficacy). In Class B responses, classic estrogens are potent agonists, and TM acts more like an agonist (Ն50% agonist efficacy). In Class C responses, TM and ethinyl E2 are potent agonists, but E2B and 17␤-E2 are inactive at doses evoking maximal Class A effects.
It should be noted that E effects on some targets (e.g. BMD and IGF-I) seem to involve integration of multiple classes (A Responses in which conventional estrogens act as potent agonists and tamoxifen predominantly acts as an antagonist with less than 33% the agonist efficacy of estrogens. Conventional estrogens include 17␤-estradiol, estradiol benzoate (E2B) and ethinyl estradiol. Class B:
Responses in which tamoxifen predominantly acts as an agonist with Ն50% the agonist efficacy of conventional estrogens. Class C:
Responses in which tamoxifen and ethinyl estradiol are potent agonists, and E2B and 17␤-estradiol are inactive at doses yielding maximal agonist effects in Class A responses.
Classification Examples in the Gonadectomized Rat b
Class A: E2B induction of pituitary PRL.
(T 3 -independent) E2B induction of anterior pituitary glandular kallikrein.
(T 3 -independent) E2B induction of uterine wet or dry weight.
(T 3 -independent) E2B suppression of serum IGF-I in hypothyroid rats.
(T 3 -independent) E2B-evoked increase in BMD in hypothyroid male rats.
(T 3 -independent) E2B induction of anterior pituitary hyperplasia.
(T 3 -dependent)
Class B: E2B or tamoxifen suppression of somatic growth.
(T 3 -dependent) E2B or tamoxifen effects to increase serum triglycerides.
(T 3 -dependent) E2B or tamoxifen inhibition of T 3 induction of serum IGF-I.
(T 3 -dependent) E2B or tamoxifen suppression of LH secretion.
(T 3 -independent)
Class C: Tamoxifen-evoked decreases in serum cholesterol.
(T 3 -independent)
a Pharmacological classes may be related to differences in the ER subtypes or ER effectors involved in the estrogen response, and interplay with other hormone signaling networks.
b Estrogen effects on some parameters in vivo may reflect the integrated contributions of multiple classes of estrogen responses. and B). Moreover, the various classes may partly reflect the ER subtype involved. For example, both ER␣ and ER␤ exhibit Class A pharmacology on model genes regulated via E response elements (85) (86) (87) (88) (89) . However, in models regulated by transcription factor AP-1, ER␣ exhibits Class B pharmacology while ER␤ exhibits Class C pharmacology (88); ER␤ also exhibits Class C pharmacology in certain other models (89) . Systematic characterization of in vivo E responses using a larger number of distinctive ER ligands may further refine the pharmacological classification.
